Alcon has filed a patent for an ophthalmic composition that delivers drugs using artificial tears. The composition includes galactomannan, a buffering agent, and a cis-diol, and is free of borate. The formulation has an osmolality between 240 mOsm/kg and 110 mOsm/kg. The galactomannan concentration is between 0.16 w/v % and 0.19 w/v %, the buffering agent concentration is between 0.1 w/v % and 0.2 w/v %, and the cis-diol concentration is between 0.5 w/v % and 5.0 w/v %. The galactomannan options include guar, hydroxylpropyl guar, and combinations thereof. The buffering agent includes a bis-aminopolyol of formula (I) or a salt thereof. GlobalData’s report on Alcon gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Alcon Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alcon, Prosthetic cardiac valves was a key innovation area identified from patents. Alcon's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230310615A1) describes an ophthalmic composition that is free of borate and includes a galactomannan, a buffering agent, and a cis-diol. The galactomannan, such as guar or hydroxylpropyl guar, is present at a concentration of 0.16% to 0.19%, while the buffering agent is present at a concentration of 0.1% to 0.2%. The cis-diol, specifically sorbitol, is present at a concentration of 0.5% to 5.0%. The composition also includes at least one demulcent, such as glycerin, polyvinyl pyrrolidone, or propylene glycol. Propylene glycol and polyethylene glycol 400 are specifically mentioned as demulcents in this patent. The pH value of the composition is between 6.5 and 8.5. The ophthalmic composition may also include an anesthetic drug, glaucoma therapeutics, pain reliever, anti-hypertensive agent, neuro-protective agent, muco-secretagogue, angiostatic agent, anti-angiogenesis agent, growth factor, immunosuppressant agent, anti-infective agent, antiviral agent, anti-inflammatory agent, anti-myopia agent, anti-allergy agent, dopaminergic antagonist, protein, anti-microbial, cooling agent, antioxidant, nutriceutical, omega-3 fatty acid, omega-6 fatty acid, vitamin A, vitamin D, vitamin E, tocopherols, vitamin K, beta-carotene, or combinations thereof. The ophthalmic composition has an osmolality in the range of 220 mOsm/kg to 170 mOsm/kg or 215 mOsm/kg to 190 mOsm/kg. It contains less than 0.1% W/V of borate and no preservative.

Additionally, the patent describes an ophthalmic emulsion that includes water forming an aqueous phase, oil forming an oil phase, a hydrophilic surfactant with an HLB value of 10 to 18, a hydrophobic surfactant with an HLB value of 1 to 6, a charged phospholipid, a mucoadhesive galactomannan polymer, a cis-diol, and a bis-aminopolyol of formula (I) or a salt thereof.

This patent presents a novel ophthalmic composition that is free of borate and includes specific concentrations of galactomannan, buffering agent, and cis-diol. The composition may also include various demulcents and other active ingredients. The pH value and osmolality of the composition are within specific ranges. The patent also describes an ophthalmic emulsion with specific components. This invention has the potential to provide improved ophthalmic formulations for various applications, including drug delivery and treatment of eye conditions.

To know more about GlobalData’s detailed insights on Alcon, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies